Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Lipitor Lawsuit Motion to Consolidate Denied
  • USA - English


News provided by

Levin, Papantonio, et al.

Aug 19, 2013, 17:00 ET

Share this article

Share toX

Share this article

Share toX


Pensacola, Fla. (PRWEB) August 19, 2013 -- A plaintiff’s motion to consolidate* was denied by a federal judicial panel for Lipitor on Aug. 8, with the Judge citing too few Lipitor lawsuit claims as the reason for the denial. The Judge ruled the Lipitor lawsuit claims in the MDL request could be voluntarily handled with Lipitor’s manufacturer.

...Lipitor's manufacturer was aware of the increased risk of patients developing type-2 diabetes while taking Lipitor, but failed to adequately disclose the risk to consumers and prescribing physicians

Post this

Despite the denial of Lipitor’s motion to consolidate, the Levin, Papantonio law firm is continuing to investigate the connection between Lipitor (atorvastatin), an anti-cholesterol drug, and type-2 diabetes, and Lipitor lawsuit claims are being filed on behalf of individuals who were injured as a result of taking Lipitor. At this time, numerous Lipitor lawsuit claims have been filed, and many more are expected to be filed in the future.

In 2012, Yunsheng Ma and his team of researchers at the University of Massachusetts Medical School conducted a study** from 1993 to 2005 that included the collection of data from approximately 150,000 women who were taking Lipitor or another statin drug, with the average age of the women being 63. The study concluded that individuals taking Lipitor or other statin drugs, and particularly postmenopausal women, were more likely to develop type-2 diabetes compared to those not taking a statin drug.

Lipitor is the most popular cholesterol-controlling drug available on the market. Since its introduction onto the market in 1996, Lipitor has been the most profitable drug in pharmaceutical history.

“According to allegations of the Lipitor lawsuit claims filed, Lipitor's manufacturer was aware of the increased risk of patients developing type-2 diabetes while taking Lipitor, but failed to adequately disclose the risk to consumers and prescribing physicians,” commented Daniel Nigh, a Lipitor lawyer with Levin, Papantonio.

In 2012, the Food and Drug Administration (FDA) issued a drug safety communication*** regarding Lipitor, and ordering a label change for the drug to reflect its link to type-2 diabetes.

If you or a loved one has developed type-2 diabetes while taking Lipitor, then you may have a case to file Lipitor lawsuit. Please do not hesitate to contact us concerning your situation, and an experienced Lipitor lawyer can help you determine if you have a case. Please visit our site for more information.

  • Daniel Nigh is an attorney with the Levin, Papantonio law firm.

SOURCES:

*MDL Request, 2013
-Evalina Smalls v. Pfizer Inc., District of South Carolina, Civil Action No. 2:13-cv-796-RMG
-Waltraud Gina Kane v. Pfizer Inc., District of South Carolina, Civil Action No. 2:13-cv-1012-RMG
-Susan Marie Turner v. Pfizer Inc., District of South Carolina, Civil Action No. 2:13-cv-01108-RMG
Available at: lipitorlawsuithelp.com/motion-to-consolidate-filed-in-lipitor-lawsuit/ -

**Annie L. Culver, Ira S. Ockene, Raji Balasubramanian, Barbara C. Olendzki, Deidre M. Sepavich, Jean Wactawski-Wende, JoAnn E. Manson, Yongxia Qiao, Simin Liu, Philip A. Merriam, Catherine Rahilly-Tierny, Fridtjof Thomas, Jeffrey S. Berger, Judith K. Ockene, J. David Curb, and Yunsheng Ma. "Statin Use and Risk of Diabetes Mellitus in Postmenopausal Women in the Women's Health Initiative" Archives of Internal Medicine (2012).
Available at: works.bepress.com/may/80

***FDA Safety Communication Concerning Label Change on Statin Drugs, 2012
Available at: fda.gov/drugs/drugsafety/ucm293101.htm

ABOUT LEVIN, PAPANTONIO LAW FIRM

Since opening its doors in 1955, the law firm of Levin, Papantonio, Thomas, Mitchell, Rafferty & Proctor, P.A. has handled many cases in mass tort litigation. Total settlements and verdicts won by the firm have exceeded $1 billion, and Levin, Papantonio was recognized by the National Law Journal in 2002 as the fourth most successful law firm in the country.

The firm presently employs 39 attorneys who specialize in various litigations, including products liability, personal injury, car accidents, and defective drugs and devices.

CONTACT
Levin, Papantonio, Thomas, Mitchell, Rafferty & Proctor, P.A.
316 South Baylen Street, Suite 600
Pensacola, FL 32502-5996
Toll Free: (888) 435-7001
Local: (850) 435-7000
Fax: (850) 497-7057

Daniel Nigh, Levin, Papantonio, et al., http://www.lipitorlawsuithelp.com, 8504357012, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.